Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) kicked off on Tuesday, up 1.06% from the previous trading day, before settling in for the closing price of $31.21. Over the past 52 weeks, TEVA has traded in a range of $12.47-$31.28.
During the last 5-year period, the sales drop of Healthcare Sector giant was -9.65%. While this was happening, its average annual earnings per share was recorded 6.20%. With a float of $1.14 billion, this company’s outstanding shares have now reached $1.15 billion.
Let’s determine the extent of company efficiency that accounts for 36167 employees.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Teva- Pharmaceutical Industries Ltd. ADR is 0.16%, while institutional ownership is 58.27%. The most recent insider transaction that took place on Dec 16 ’25, was worth 371,504. In this transaction Chief Accounting Officer of this company sold 12,300 shares at a rate of $30.20, taking the stock ownership to the 5,650 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Director sold 77,400 for $30.24, making the entire transaction worth $2,340,646. This insider now owns 367,600 shares in total.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.71 earnings per share (EPS), higher than consensus estimate (set at 0.7) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.99% during the next five years compared to -9.65% drop over the previous five years of trading.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
Take a look at Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) current performance indicators. Last quarter, stock had a quick ratio of 0.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.15. Likewise, its price to free cash flow for the trailing twelve months is 144.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.61, a number that is poised to hit 0.65 in the next quarter and is forecasted to reach 2.77 in one year’s time.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Looking closely at Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA), its last 5-days average volume was 10.05 million, which is a drop from its year-to-date volume of 11.75 million. As of the previous 9 days, the stock’s Stochastic %D was 95.00%.
During the past 100 days, Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) raw stochastic average was set at 99.75%, which indicates a significant increase from 98.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was higher than the 0.59 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.77, while its 200-day Moving Average is $18.92. However, in the short run, Teva- Pharmaceutical Industries Ltd. ADR’s stock first resistance to watch stands at $31.69. Second resistance stands at $31.83. The third major resistance level sits at $32.09. If the price goes on to break the first support level at $31.29, it is likely to go to the next support level at $31.03. Now, if the price goes above the second support level, the third support stands at $30.89.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Key Stats
The company with the Market Capitalisation of 36.17 billion has total of 1,146,960K Shares Outstanding. Its annual sales at the moment are 16,544 M in contrast with the sum of -1,639 M annual income. Company’s last quarter sales were recorded 4,480 M and last quarter income was 433,000 K.
